APO-50815 is a potent and selective WEE1 kinase inhibitor with IC50 of 9 nM, 10-fold selective over PLK1 and does not inhibit CHK1. APO-50815 demonstrates exceptional anticancer efficacy against the peritoneal mCRC PDO lines PM003 and PM025 with GI50 of 37 nM and 74 nM respectively. APO-50815 shows potent activity against TP53-mutated CRC PDO lines derived from liver metastases, abrogate CDK1 phosphorylation in MDA-MB-231HM cancer cells.
